Business Wire

MA-ONPROCESS-TECHNOLOGY

Share
OnProcess and Baxter Planning Forge Strategic Product and Commercial Partnership

OnProcess Technology (www.onprocess.com ), a global pioneer powering the world’s circular service supply chains, today announced the formation of a new strategic commercial and product partnership with Baxter Planning (www.baxterplanning.com ). The partnership includes joint investment in the two companies’ technology roadmaps, a commitment to integrating certain product offerings, and a combined commercial approach.

The partnership is in response to what both companies see as growing industry calls to deliver and manage best-in-class service supply chains. As a result of several macroeconomic factors - global supply chain uncertainties, growing demand for sustainable practices, increasing e-waste legislation, the continued move to servitization, as well as higher cost of goods driven by rising interest rates and inflation - both companies cite that there has never been more focus on the role that the service supply chains play.

OnProcess and Baxter Planning have aligned views around the need to speed up the digitalization across the three main functions of the service supply chain:

  • Planning (ensuring inventory levels are available in the right places to meet service-level commitments/SLAs)
  • Delivering (ensuring inventory is delivered efficiently, to customers or other end-users, according to SLAs) and
  • Recovering (ensuring that the maximum value is recovered from assets no longer required in the field, whether that inventory is unused, in need of repair/refurbishment/recycling, or for warranty recovery)

And putting Customer Experience at the heart of the service event.

The two companies recognize that to solve the complexities of the service supply chain requires a foundation built on aggregated data, and a platform that integrates and gathers that data from otherwise siloed operational sources. Only then can the three functional areas of Planning, Delivery and Recovery fully work together and provide a seamless view of the whole service supply chain. This results in smarter decisions, frictionless customer experiences, and a circular model that helps drive towards sustainability goals and targets.

With Baxter’s long-established record as a leader in the inventory planning market, and OnProcess’s reputation as a full-service provider to some of the world’s most recognised brands, the two companies have committed to further integrating their respective product offerings, such as Baxter Planning’s Prophet for service parts planning, and OnProcess’s Agora platform.

“We are excited to announce this very strategic partnership with Baxter,” said Oliver Lemanski, CEO, OnProcess. “Their deep domain expertise in service inventory planning, along with their market-leading software products, makes a natural fit with OnProcess, and in particular our technology platform Agora . We are on a mission to power the world’s circular service supply chains across a seamless process flow of Planning, Delivery and Recovery, and to do that we welcome partnerships, such as this with Baxter, to help us deliver on our promise .

“OnProcess has an enviable reputation in the service supply chain market, with some of the world’s most recognized brands as their clients,” stated Chuck Moeling, CEO, Baxter Planning. “As a best-of-breed planning provider, we see only synergy with OnProcess’s focus on Delivery and Recovery. We look forward to deepening our relationship and further developing our respective products so we can provide our mutual customers the very best the market has to offer .

About OnProcess Technology, Inc.

OnProcess supplies technology and services that power the world’s circular service supply chains. Delivering through the Agora™ platform, OnProcess streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals for many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies. For more information please visit www.onprocess.com .

About Baxter Planning

Founded in 1993, Baxter Planning was built expressly for the service supply chain. Their software is developed based on proven best practices, industry expertise, and a partnership with customers to automate inventory planning. Their Total Cost Optimization methodology replaces spreadsheets and manual processes to deliver the best service level at the lowest possible cost. As a worldwide leader in Service Supply Chain software, Baxter Planning helps customers plan billions in service parts inventory every day. For more information, visit http://www.baxterplanning.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye